Clinical trials: SARS-CoV-2 Infections
COVID-19
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
- Trial name
- NCT04395391
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
COVID-19 Pandemic
Intranasal INNA-051 for Prevention of COVID-19 in Adults
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection.
- Trial name
- NCT05118763
- Testing
- INNA-051
- Volunteers
- healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
Coronavirus Infection, COVID
Monovalent Recombinant COVID19 Vaccine
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2.
- Trial name
- COVAX19 (NCT04453852)
- Testing
- COVID19 vaccine, Saline
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
COVID-19
Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine
Phase 3 Study Comparing Safety and Immune Response of Three Batches of Novavax Flu Vaccine in older adult participants
- Trial name
- NCT06485752
- Testing
- tNIV 1 and Matrix-M Adjuvant
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.
- Trial name
- NCT05938075
- Testing
- VXCO-100, COVID-19 mRNA vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
COVID-19
Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
This exploratory study is a randomized, single center, open label study of four different experimental treatment arms versus standard of care for the treatment of SARS-CoV-2 infection in symptomatic outpatients with mild disease…
- Trial name
- NCT04532931
- Testing
- Paracetamol, Artesunate-amodiaquine, Pyronaridine-artesunate
- Where
- South Africa
- Volunteers
- 192 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
SARS-CoV-2
Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1.
- Trial name
- NCT04639375
- Testing
- Vaccinated with polio vaccine (IPV)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- E-MO Biology Inc
Covid19
Text Message Nudges for COVID-19 Vaccination
The COVID-19 pandemic has caused significant morbidity and mortality across the world. Effective vaccines are now available but underutilized.
- Trial name
- NCT05037201
- Testing
- Text message
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Mitesh Patel
Immunity, Vaccine Reaction
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions.
- Conditions
- Immunity, Vaccine Reaction, Influenza, Covid19
- Trial name
- NCT04798677
- Testing
- ABBC1 Immunoessential
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AB Biotek
COVID-19 Pandemic
A Study of FB2001 for Inhalation in Healthy Chinese Adults
FB2001 is a novel inhalable preparation being developed for COVID-19 treatment. A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and…
- Trial name
- NCT05583812
- Testing
- FB2001 for inhalation
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19 SARS-CoV-2 Infection, COVID-19
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to…
- Conditions
- COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19)
- Trial name
- NCT06923137
- Testing
- BNT162b2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Novel COVID-19-Infected Pneumonia
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
A randomized, double-blind, placebo parallel control study and is expected to enroll 20-60 eligible patients with severe novel coronavirus pneumonia.
- Trial name
- COVID-19 (NCT05688839)
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
COVID-19 Pandemic
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
This is a randomized, double-blinded, placebo-controlled, dose-escalation study to valuate the safety and immunogenicity of RH109 as booster at 2 dose levels for ealthy adults who have received homologous or heterologous…
- Trial name
- NCT05609045
- Testing
- Lyophilized COVID-19 mRNA Vaccine, Sodium chloride
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wuhan Rhegen Biotechnology Co., Ltd.
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR C19 IL (NCT05712096)
- Testing
- EVUSHELD
- Where
- Israel
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
COVID-19 Infection
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone…
- Trial name
- NCT07013474
- Testing
- ibuzatrelvir, remdesivir
- Where
- 159 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Coronavirus, COVID
Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar
Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus.
- Conditions
- Coronavirus, COVID, Pneumonia
- Trial name
- DOLCI (NCT04425382)
- Testing
- Darunavir/Cobicistat, Lopinavir/Ritonavir
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
COVID-19
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
To develop an effective vaccine against the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Clover Biopharmaceuticals is conducting a Phase 1 study (CLO-SCB-2019-001) in healthy volunteers to evaluate the…
- Trial name
- NCT04932824
- Testing
- SCB-2019
- Where
- Australia
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID - 19
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
- Trial name
- NCT07728396
- Testing
- GC4006A, Normal Saline
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.